FSCN1 and non-small cell lung carcinoma: Zhang et al. found that exosomal circSATB2 could facilitate the progression of NSCLC through the miR-326/FSCN1 pathway, and serum exosomal circSATB2 was higher in metastatic clinical serum samples, which obtained an AUC of 0.797 in distinguishing lymphatic metastatic NSCLC [136].